Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 213

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier

Open access
Wong, Ka Hong, Riaz, Muhammad Kashif, Xie, Yuning, Zhang, Xue, Liu, Qiang, Chen, Huoji, Bian, Zhaoxiang, Chen, Xiaoyu, Lu, Aiping, Yang, Zhijun · 2019 · International Journal of Molecular Sciences

Abstract

Effective therapy for Alzheimer’s disease is a major challenge in the pharmaceutical sciences. There are six FDA approved drugs (e.g., donepezil, memantine) that show some effectiveness; however, they only relieve symptoms. Two factors hamper research. First, the cause of Alzheimer’s disease is not fully understood. Second, the blood-brain barrier restricts drug efficacy. This review summarized current knowledge relevant to both of these factors. First, we reviewed the pathophysiology of Alzheimer’s disease. Next, we reviewed the structural and biological properties of the blood-brain barrier. We then described the most promising drug delivery systems that have been developed in recent years; these include polymeric nanoparticles, liposomes, metallic nanoparticles and cyclodextrins. Overall, we aim to provide ideas and clues to design effective drug delivery systems for penetrating the blood-brain barrier to treat Alzheimer’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20020381

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 109

  1. 2007, Current Therapeutic Options for Alzheimer’s Disease, Curr. Genom., 8, 550, 10.2174/138920207783769549 · DOI
  2. Swanson, 2018, Treatment of early AD subjects with BAN2401, an anti-Aβ protofibril monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline, Alzheimer’s Dement., 14, P1668, 10.1016/j.jalz.2018.07.009 · DOI
  3. Redzic, 2011, Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: Similarities and differences, Fluids Barriers CNS, 8, 3, 10.1186/2045-8118-8-3 · DOI · Paper page
  4. Sercombe, 2015, Advances and Challenges of Liposome Assisted Drug Delivery, Front. Pharmacol., 6, 286, 10.3389/fphar.2015.00286 · DOI · Paper page
  5. Tiwari, 2012, Drug delivery systems: An updated review, Int. J. Pharm. Investig., 2, 2, 10.4103/2230-973X.96920 · DOI · Paper page
  6. Goh, 2013, Changes in Brain Function Occur Years before the Onset of Cognitive Impairment, J. Neurosci., 33, 18008, 10.1523/JNEUROSCI.1402-13.2013 · DOI · Paper page
  7. Oh, 2014, Neural compensation in older people with brain amyloid-β deposition, Nat. Neurosci., 17, 1316, 10.1038/nn.3806 · DOI · Paper page
  8. Sun, 2015, β-Amyloid: The key peptide in the pathogenesis of Alzheimer’s disease, Front. Pharmacol., 6, 221, 10.3389/fphar.2015.00221 · DOI · Paper page
  9. Louise, 2000, Alzheimer’s amyloid fibrils: Structure and assembly, BBA—Mol. Basis Dis., 1502, 16, 10.1016/S0925-4439(00)00029-6 · DOI · Paper page
  10. Singh, 2016, Overview of Alzheimer’s Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds, Oxidative Med. Cell. Longev., 2016, 1, 10.1155/2016/7361613 · DOI · Paper page
  11. Wang, F., Zhou, X.-L., Yang, Q.-G., Xu, W.-H., Wang, F., Chen, Y.-P., and Chen, G.-H. (2011). A Peptide That Binds Specifically to the β-Amyloid of Alzheimer’s Disease: Selection and Assessment of Anti-β-Amyloid Neurotoxic Effects. PLoS ONE, 6. · DOI
  12. Reddy, 2008, Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease, Trends Mol. Med., 14, 45, 10.1016/j.molmed.2007.12.002 · DOI · Paper page
  13. Butterfield, 2013, Amyloid β-Peptide (1–42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression, Antioxid. Redox Signal., 19, 823, 10.1089/ars.2012.5027 · DOI · Paper page
  14. Masahir, K., Isao, O., Shoko, Y., Midori, K., and Yutaka, S. (2011). Membrane Incorporation, Channel Formation, and Disruption of Calcium Homeostasis by Alzheimer’s β-Amyloid Protein. Int. J. Alzheimer’s Dis., 2011. · DOI
  15. Demuro, 2010, Calcium signaling and amyloid toxicity in Alzheimer disease, J. Biol. Chem., 285, 12463, 10.1074/jbc.R109.080895 · DOI · Paper page
  16. Diniz, 2009, Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both?, Dement. Neuropsychol., 3, 188, 10.1590/S1980-57642009DN30300003 · DOI
  17. Gong, 2008, Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease, Curr. Med. Chem., 15, 2321, 10.2174/092986708785909111 · DOI · Paper page
  18. Liu, 2013, Apolipoprotein E and Alzheimer disease: Risk, mechanisms, and therapy, Nat. Rev. Neurol., 9, 106, 10.1038/nrneurol.2012.263 · DOI · Paper page
  19. Boucau, 2018, ABCA7 downregulation modifies cellular cholesterol homeostasis and decreases amyloid-β peptide efflux in an in vitro model of the blood-brain barrier, J. Alzheimer’s Dis., 64, 1195, 10.3233/JAD-170883 · DOI · Paper page
  20. Rodriguez, 2010, The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: The former opens to the portal blood and the latter to the cerebrospinal fluid, Peptides, 31, 757, 10.1016/j.peptides.2010.01.003 · DOI · Paper page
  21. Volterra, 2005, Astrocytes, from brain glue to communication elements: The revolution continues, Nat. Rev. Neurosci., 6, 626, 10.1038/nrn1722 · DOI · Paper page
  22. Peppiatt, 2006, Bidirectional control of CNS capillary diameter by pericytes, Nature, 443, 700, 10.1038/nature05193 · DOI · Paper page
  23. Chen, 2012, Modern methods for delivery of drugs across the blood-brain barrier, Adv. Drug Deliv. Rev., 64, 640, 10.1016/j.addr.2011.11.010 · DOI · Paper page
  24. Fischer, 1998, Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion, J. Membr. Biol., 165, 201, 10.1007/s002329900434 · DOI · Paper page
  25. Rishton, 2006, Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer’s disease, Curr. Opin. Drug Discov. Dev., 9, 303
  26. Kelder, 1999, Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs, Pharm. Res., 16, 1514, 10.1023/A:1015040217741 · DOI · Paper page
  27. Alam, 2010, Strategy for effective brain drug delivery, Eur. J. Pharm. Sci., 40, 385, 10.1016/j.ejps.2010.05.003 · DOI · Paper page
  28. Fong, 2015, Permeability of the Blood-Brain Barrier: Molecular Mechanism of Transport of Drugs and Physiologically Important Compounds, J. Membr. Biol., 248, 651, 10.1007/s00232-015-9778-9 · DOI · Paper page
  29. Simpson, 2001, Glucose transporter asymmetries in the bovine blood-brain barrier, J. Biol. Chem., 276, 12725, 10.1074/jbc.M010897200 · DOI · Paper page
  30. Pardridge, 1992, Recent developments in peptide drug delivery to the brain, Pharmacol. Toxicol., 71, 3, 10.1111/j.1600-0773.1992.tb00512.x · DOI
  31. Bickel, 2001, Delivery of peptides and proteins through the blood-brain barrier, Adv. Drug Deliv. Rev., 46, 247, 10.1016/S0169-409X(00)00139-3 · DOI · Paper page
  32. Kumagai, 1987, Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport, J. Biol. Chem., 262, 15214, 10.1016/S0021-9258(18)48160-4 · DOI · Paper page
  33. Kokryakov, 1993, Protegrins: Leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins, FEBS Lett., 327, 231, 10.1016/0014-5793(93)80175-T · DOI · Paper page
  34. Drin, 2002, Peptide delivery to the brain via adsorptive-mediated endocytosis: Advances with SynB vectors, AAPS Pharmsci., 4, 61, 10.1208/ps040426 · DOI
  35. Rousselle, 2001, Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: Saturation kinetics and specificity, J. Pharmacol. Exp. Ther., 296, 124
  36. Rousselle, 2002, Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy, J. Drug Target., 10, 309, 10.1080/10611860290031886 · DOI
  37. Brodin, 1997, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J. Biol. Chem., 272, 16010, 10.1074/jbc.272.25.16010 · DOI · Paper page
  38. Wender, 2000, The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. USA, 97, 13003, 10.1073/pnas.97.24.13003 · DOI · Paper page
  39. Santra, 2005, Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots, Chem. Commun., 25, 3144, 10.1039/b503234b · DOI · Paper page
  40. Catania, 2016, Tackling amyloidogenesis in Alzheimer’s disease with A2V variants of Amyloid-β, Sci. Rep., 6, 20949, 10.1038/srep20949 · DOI
  41. Giunta, 2009, HIV-1 Tat contributes to Alzheimer’s disease-like pathology in PSAPP mice, Int. J. Clin. Exp. Pathol., 2, 433
  42. Hategan, 2017, HIV-Tat protein and amyloid β peptide form multifibrillar structures that cause neurotoxicity, Nat. Struct. Mol. Biol., 24, 379, 10.1038/nsmb.3379 · DOI
  43. Wu, 2015, Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer’s Rodent Models, Sci. Rep., 5, 15032, 10.1038/srep15032 · DOI
  44. Cheng, 2017, An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice, Embo Mol. Med., 9, 703, 10.15252/emmm.201606666 · DOI
  45. Hennink, 2011, In Vivo Methods to Study Uptake of Nanoparticles into the Brain, Pharm. Res., 28, 456, 10.1007/s11095-010-0291-7 · DOI
  46. Moos, 2000, Transferrin and transferrin receptor function in brain barrier systems, Cell. Mol. Neurobiol., 20, 77, 10.1023/A:1006948027674 · DOI · Paper page
  47. Kalaria, 1992, Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer’s disease, Brain Res., 585, 87, 10.1016/0006-8993(92)91193-I · DOI
  48. Zhang, 2001, Rapid transferrin efflux from brain to blood across the blood-brain barrier, J. Neurochem., 76, 1597, 10.1046/j.1471-4159.2001.00222.x · DOI · Paper page
  49. Gaillard, 2007, Drug targeting to the brain, Annu. Rev. Pharmacol. Toxicol., 47, 323, 10.1146/annurev.pharmtox.47.120505.105237 · DOI · Paper page
  50. Saito, 1995, Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex, Proc. Natl. Acad. Sci. USA, 92, 10227, 10.1073/pnas.92.22.10227 · DOI · Paper page
  51. Pardridge, 1998, Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, Pharm. Res., 15, 576, 10.1023/A:1011981927620 · DOI
  52. Boado, 1998, Drug delivery of antisense molecules to the brain for treatment of Alzheimer’s disease and cerebral AIDS, J. Pharm. Sci., 87, 1308, 10.1021/js9800836 · DOI
  53. Lee, 2000, Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse, J. Pharmacol. Exp. Ther., 292, 1048
  54. Pardridge, 1985, Human blood-brain barrier insulin receptor, J. Neurochem., 44, 1771, 10.1111/j.1471-4159.1985.tb07167.x · DOI · Paper page
  55. Shiiki, 2004, Brain insulin impairs amyloid-beta(1-40) clearance from the brain, J. Neurosci., 24, 9632, 10.1523/JNEUROSCI.2236-04.2004 · DOI
  56. Xie, 2002, Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor, J. Neurosci., 22, RC221, 10.1523/JNEUROSCI.22-10-j0001.2002 · DOI · Paper page
  57. Pardridge, 1995, Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate, Pharm. Res., 12, 807, 10.1023/A:1016244500596 · DOI · Paper page
  58. Coloma, 2000, Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor, Pharm. Res., 17, 266, 10.1023/A:1007592720793 · DOI · Paper page
  59. Hwang, 2005, Immunogenicity of engineered antibodies, Methods, 36, 3, 10.1016/j.ymeth.2005.01.001 · DOI · Paper page
  60. Boado, 2007, Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier, Biotechnol. Bioeng., 96, 381, 10.1002/bit.21120 · DOI · Paper page
  61. Boado, 2007, Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation, Bioconjug. Chem., 18, 447, 10.1021/bc060349x · DOI
  62. Boado, 2010, IgG-Single Chain Fv Fusion Protein Therapeutic for Alzheimer’s Disease: Expression in CHO Cells and Pharmacokinetics and Brain Delivery in the Rhesus Monkey, Biotechnol. Bioeng., 105, 627, 10.1002/bit.22576 · DOI
  63. Ohshima-Hosoyama, S., Simmons, H.A., Goecks, N., Joers, V., Swanson, C.R., Bondarenko, V., Velotta, R., Brunner, K., Wood, L.D., and Hruban, R.H. (2012). A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. PLoS ONE, 7. · DOI
  64. Bu, 1994, Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons, J. Biol. Chem., 269, 18521, 10.1016/S0021-9258(17)32340-2 · DOI · Paper page
  65. Gaillard, 2005, Targeted delivery across the blood-brain barrier, Expert Opin. Drug Deliv., 2, 299, 10.1517/17425247.2.2.299 · DOI
  66. Frautschy, 2005, Low density lipoprotein receptor-related proteins (LRPs), Alzheimer’s and cognition, Curr. Drug Targets CNS Neurol. Disord., 4, 469, 10.2174/156800705774322102 · DOI · Paper page
  67. Hughes, 1998, Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation, Proc. Natl. Acad. Sci. USA, 95, 3275, 10.1073/pnas.95.6.3275 · DOI · Paper page
  68. Narita, 1997, Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein, J. Neurochem., 69, 1904, 10.1046/j.1471-4159.1997.69051904.x · DOI · Paper page
  69. Blacker, 1998, Alpha-2 macroglobulin is genetically associated with Alzheimer disease, Nat. Genet., 19, 357, 10.1038/1243 · DOI · Paper page
  70. Chen, 2010, Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery, Eur. J. Pharm. Sci., 40, 94, 10.1016/j.ejps.2010.03.007 · DOI
  71. Huang, 2007, Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain, J. Biomed. Sci., 14, 121, 10.1007/s11373-006-9121-7 · DOI
  72. Kawamata, 1993, Lactotransferrin immunocytochemistry in Alzheimer and normal human brain, Am. J. Pathol., 142, 1574
  73. Kennard, 1996, Serum levels of the iron binding protein p97 are elevated in Alzheimer’s disease, Nat. Med., 2, 1230, 10.1038/nm1196-1230 · DOI · Paper page
  74. Demeule, 2002, High transcytosis of melanotransferrin (P97) across the blood-brain barrier, J. Neurochem., 83, 924, 10.1046/j.1471-4159.2002.01201.x · DOI · Paper page
  75. Richardson, 2004, Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood–brain barrier, Int. Congr. Ser., 1277, 171
  76. Pan, 2004, Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier, J. Cell Sci., 117, 5071, 10.1242/jcs.01381 · DOI
  77. Choi, 2011, Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability, Proc. Natl. Acad. Sci. USA, 108, 9256, 10.1073/pnas.1018790108 · DOI · Paper page
  78. Raliya, 2017, Non-invasive aerosol delivery and transport of gold nanoparticles to the brain, Sci. Rep., 7, 44718, 10.1038/srep44718 · DOI
  79. Hanson, L.R., Fine, J.M., Svitak, A.L., and Faltesek, K.A. (2013). Intranasal Administration of CNS Therapeutics to Awake Mice. J. Vis. Exp., 4440. · DOI · Paper page
  80. Etame, 2012, Focused ultrasound disruption of the blood-brain barrier: A new frontier for therapeutic delivery in molecular neurooncology, Neurosurg. Focus, 32, E3, 10.3171/2011.10.FOCUS11252 · DOI
  81. Gosselet, 2013, Amyloid-β peptides, Alzheimer’s disease and the blood-brain barrier, Curr. Alzheimer Res., 10, 1015, 10.2174/15672050113106660174 · DOI · Paper page
  82. Suri, 2007, Nanotechnology-based drug delivery systems, J. Occup. Med. Toxicol., 2, 16, 10.1186/1745-6673-2-16 · DOI · Paper page
  83. Sathya, 2017, Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer’s toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function, Artif. Cellsnanomed. Biotechnol., 25, 1
  84. Fornaguera, 2015, Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases, Nanoscale, 7, 12076, 10.1039/C5NR03474D · DOI
  85. Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., and Kumar, D.S. (2012). Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer’s Disease. PLoS ONE, 7. · DOI · Paper page
  86. Anand, 2010, Design of Curcumin Loaded PLGA Nanoparticles Formulation with Enhanced Cellular Uptake, and Increased Bioactivity in vitro and Superior Bioavailability in vivo, Biochem. Pharmacol., 79, 330, 10.1016/j.bcp.2009.09.003 · DOI · Paper page
  87. Huang, 2017, PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice, Oncotarget, 8, 81001, 10.18632/oncotarget.20944 · DOI · Paper page
  88. Ettcheto, 2017, New potential strategies for Alzheimer’s disease prevention: Pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9, Nanomedicine, 13, 1171, 10.1016/j.nano.2016.12.003 · DOI
  89. Carradori, 2018, Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer’s disease-like transgenic mouse model, Nanomedicine, 14, 609, 10.1016/j.nano.2017.12.006 · DOI
  90. Akbarzadeh, 2013, Liposome: Classification, preparation, and applications, Nanoscale Res. Lett., 8, 102, 10.1186/1556-276X-8-102 · DOI · Paper page
  91. Milla, 2012, PEGylation of proteins and liposomes: A powerful and flexible strategy to improve the drug delivery, Curr. Drug Metab., 13, 105, 10.2174/138920012798356934 · DOI · Paper page
  92. Mutlu, 2011, New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations, Drug Dev. Ind. Pharm., 37, 775, 10.3109/03639045.2010.541262 · DOI
  93. Zheng, 2015, Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease, Pharm. Res., 32, 3837, 10.1007/s11095-015-1744-9 · DOI · Paper page
  94. Chen, 2016, Transferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrier, Nanomedicine, 12, 421, 10.1016/j.nano.2015.10.021 · DOI
  95. Kuo, 2014, Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin, Biomaterials, 35, 5954, 10.1016/j.biomaterials.2014.03.082 · DOI
  96. Kuo, 2017, Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin, Int. J. Nanomed., 12, 2857, 10.2147/IJN.S132472 · DOI
  97. Markoutsa, 2014, Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies, Pharm. Res., 31, 1275, 10.1007/s11095-013-1249-3 · DOI
  98. Mourtas, 2014, Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease, Eur. J. Med. Chem., 80, 175, 10.1016/j.ejmech.2014.04.050 · DOI · Paper page
  99. Shankar, 2016, A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: Formation mechanism and applications, Enzym. Microb. Technol., 95, 28, 10.1016/j.enzmictec.2016.10.015 · DOI · Paper page
  100. Yuna, 2016, How Do the Size, Charge and Shape of Nanoparticles Affect Amyloid β Aggregation on Brain Lipid Bilayer?, Sci. Rep., 6, 19548, 10.1038/srep19548 · DOI
  101. Rai, 2018, A nanoformulation for the preferential accumulation in adult neurogenic niches, J. Control Release, 284, 57, 10.1016/j.jconrel.2018.06.013 · DOI
  102. Nan, 2015, Gold-Nanoparticle-Based Multifunctional Amyloid-b Inhibitor against Alzheimer’s Disease, Chemistry, 21, 829, 10.1002/chem.201404562 · DOI · Paper page
  103. Coisne, C., Tilloy, S., Monflier, E., Wils, D., Fenart, L., and Gosselet, F. (2016). Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. Molecules, 21. · DOI
  104. Yao, 2012, Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease, J. Exp. Med., 209, 2501, 10.1084/jem.20121239 · DOI · Paper page
  105. Fenyvesi, 2014, Cyclodextrins, blood-brain barrier, and treatment of neurological diseases, Arch. Med. Res., 45, 711, 10.1016/j.arcmed.2014.11.020 · DOI
  106. Tilloy, 2006, Methylated beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier, Bioorg. Med. Chem. Lett., 16, 2154, 10.1016/j.bmcl.2006.01.049 · doi:10.1016/j.bmcl.2006.01.049
  107. Gil, 2012, β-cyclodextrin-poly(β-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier, Biomacromolecules, 13, 3533, 10.1021/bm3008633 · DOI
  108. Shawahna, 2013, Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: A special focus on transporters and metabolizing enzymes, Curr. Drug Metab., 14, 120, 10.2174/138920013804545232 · DOI
  109. Zhang, 2015, Drug-in-cyclodextrin-in-liposomes: A novel drug delivery system for flurbiprofen, Int. J. Pharm., 492, 40, 10.1016/j.ijpharm.2015.07.011 · DOI

Cited by

See all 213

Metadata

Authors
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-01-17
Volume
20
Issue
2
Pages
381
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2910423533
Cited by
213
References
35
FWCI
9.25
Type
journal article
Language
en
Open access
gold
Funders
  • Hong Kong Baptist University (FRG2/16-17/073, and FRG2/15-16/078)
  • Science and Technology Planning Project of Guangdong Province (2017A050506027)
  • Science and Technology Program of Guangzhou (201807010053)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.